Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran. Idarucizumab was developed by Boehringer...
11 KB (806 words) - 05:38, 27 May 2024
In cases of severe bleeding, it can be reversed with the antidote, idarucizumab. Use is not recommended during pregnancy or breastfeeding. Compared to...
41 KB (3,733 words) - 13:41, 14 June 2024
idarucizumab (for dabigatran) and andexanet alfa (for factor Xa inhibitor) have been used in clinical settings with varying efficacy. Idarucizumab is...
78 KB (8,755 words) - 00:46, 23 July 2024
intracerebral bleeding on antiplatelet medication. The specific reversal agents idarucizumab and andexanet alfa may be used to stop continued intracerebral hemorrhage...
44 KB (4,483 words) - 09:30, 10 August 2024
III Empagliflozin SGLT-2-inhibitor Diabetes mellitus type II Approved Idarucizumab Humanized antibody fragment (FAB), specific reversal agent to dabigatran...
39 KB (3,272 words) - 11:00, 31 July 2024
oxygen therapy (HBOT) Carbon monoxide poisoning and cyanide poisoning Idarucizumab Reversal of dabigatran etexilate, an anticoagulant Insulin + Glucagon...
8 KB (523 words) - 11:51, 18 May 2024
100 mg vial) which is higher than reversal agents for other DOAC agents (idarucizumab for use in dabigatran reversal is $4,200 per reversal). "Andexxa APMDS"...
16 KB (1,367 words) - 23:56, 10 July 2024
CD20 Y non-Hodgkin's lymphoma Icrucumab mab human VEGFR-1 cancer etc. Idarucizumab Praxbind mab humanized dabigatran Y reversal of anticoagulant effects...
136 KB (4,020 words) - 07:14, 15 August 2024
Hydroxocobalamin V03AB34 Fomepizole V03AB35 Sugammadex V03AB36 Phentolamine V03AB37 Idarucizumab V03AB38 Andexanet alfa V03AB54 Pralidoxime and atropine QV03AB90 Atipamezole...
3 KB (373 words) - 00:33, 26 December 2023
Complementing these drugs are reversal agents available for dabigatran (idarucizumab), and for apixaban, and rivaroxaban (andexanet alfa). Andexanet alfa...
94 KB (9,772 words) - 05:31, 19 April 2024